ABSTRACT
This study was aimed to analyze the survival of patients with spinal chordomas. Patients' data in the Surveillance, Epidemiology, and End Results (SEER) database were retrieved and analyzed statistically. There were 765 patients with spinal chordomas between 1974 and 2013. The overall survival did not improve significantly over decades for patients receiving surgery and radiotherapy (SR) (P = 0.221). There were significant differences in overall survival among subgroups of patients receiving surgery (S), radiotherapy (R), and neither S nor R (NSR) (P = 0.031, 0.037, and 0.031, respectively). Cancer-specific survival did not change significantly among subgroups of patients receiving R (P = 0.411), while it increased steadily among subgroups of patients receiving S, SR, and NSR (P < 0.001, 0.001, and 0.049, respectively). In the multivariate Cox regression model, younger onset age (hazard ratio [HR] 1.052, P < 0.001), surgery (HR 0.291, P = 0.001), and tumor location of the sacrum (HR 0.401, P = 0.002) were associated with a better overall survival. Similarly, younger onset age (HR 1.036, P = 0.029), surgery (HR 0.221, P = 0.009), and tumor location of the sacrum (HR 0.287, P = 0.002) were also associated with a higher cancer-specific survival. The changes in overall and cancer-specific survival over time differ among different treatment groups. Younger onset age, surgical strategy, and tumor location of the sacrum may be correlated with a higher overall and cancer-specific survival.
Subject(s)
Chordoma/mortality , Spinal Neoplasms/mortality , Adult , Age of Onset , Aged , Chordoma/pathology , Chordoma/therapy , Databases, Factual , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Proportional Hazards Models , Radiosurgery , Sacrum , Spinal Neoplasms/pathology , Spinal Neoplasms/therapy , Survival Analysis , Survival RateABSTRACT
This study was aimed to reveal the changes in survival rates and prognostic factors to survival of chondroblastic osteosarcoma (COS).Patients from the Surveillance, Epidemiology, and End Results (SEER) database were retrieved. Kaplan-Meier survival analysis and Cox proportional hazard model were used during analysis.There were significant differences on overall survival between subtypes of osteosarcoma (Pâ<â.001*). Overall survival of COS did not change significantly during last forty years (Pâ=â.610), and cancer-specific survival increased to a plateau in 1980s and then remained stable (Pâ=â.058). Younger onset age, patients of white race, well and moderately differentiated tumors, and surgery independently predicted better overall (Hazard ratio [HR]: 1.034, Pâ<â.001*; HR: 0.538, Pâ=â.004*; HR: 0.240, Pâ=â.020* and HR: 0.350, Pâ<â.001*, respectively) and cancer-specific (HR: 1.031, Pâ=â.002*; HR: 0.592, Pâ=â.036*; HR: 0.098, Pâ=â.027* and HR: 0.253, Pâ<â.001*, respectively) survival. Metastasis at diagnosis independently predicted worse overall (HR: 3.108, Pâ<â.001*) and cancer-specific (HR: 4.26, Pâ<â.001*) survival compared to no metastasis.Younger onset age, white race, well and moderately differentiated tumors, no metastasis at diagnosis and surgical resection can independently predict better overall and cancer-specific survival of COS.
